bpc 157 fda approval status warning You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from Category 2 FDA takes coser look at
Description
Long-term side effects of NAD treatment have not been described

Lheureux, P

It is an acylated peptide of 39 amino acids, known in the research literature by the designation NN9838, that acts as an agonist at amylin and calcitonin receptors

WARNINGS: Patients with early Leber's disease (hereditary optic nerve atrophy) who were treated with cyanocobalamin suffered severe and swift optic atrophy
